Tag: ANGPTL8

Kyttaro, Lilly sign licence agreement for monoclonal antibody programme

Low magnification micrograph of the distal right coronary artery with complex atherosclerosis and luminal narrowing. Credit: Nephron / commons.wikipedia.org. Kyttaro has signed an agreement to obtain an exclusive global licence for Eli Lilly and Company’s anti-angiopoietin-like (ANGPTL) 3/8 monoclonal antibody programme to treat atherosclerotic cardiovascular disease (ASCVD). The antibody will…

Continue Reading Kyttaro, Lilly sign licence agreement for monoclonal antibody programme

Liver-specific knockdown of ANGPTL8 alters the structure of the gut microbiota in mice | Annals of Microbiology

Bacterial taxonomic profiling of the gut microbiota from between controls and sh-ANGPTL8. a Relative abundance of the top 10 abundant bacterial phyla in indicated individuals. b, c Heat map of the top 10 abundant bacterial phyla in indicated individuals (b) and T test results (c). d Relative abundance of Bacteroidetes….

Continue Reading Liver-specific knockdown of ANGPTL8 alters the structure of the gut microbiota in mice | Annals of Microbiology

The Potential of ANGPTL8 Antagonism to Simultaneously Reduce Triglyceride and Increase HDL-Cholesterol Plasma Levels

Elevated triglyceride (TG) and reduced high-density lipoprotein-cholesterol (HDL-C) plasma levels are risk factors for atherosclerosis and cardiovascular disease. Therefore, a drug that simultaneously reduces TG and increases HDL-C plasma levels has the potential to prevent and treat these diseases. Angiopoietin-like 3 (ANGPTL3) regulates plasma TG and HDL-C levels by inhibiting…

Continue Reading The Potential of ANGPTL8 Antagonism to Simultaneously Reduce Triglyceride and Increase HDL-Cholesterol Plasma Levels